Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy

Detalhes bibliográficos
Autor(a) principal: Gil,Ana Cecília Montes
Data de Publicação: 2007
Outros Autores: Lorenzetti,Raquel, Mendes,Gun Bergsten, Morcillo,André Moreno, Toro,Adyléia Aparecida Dalbo Contrera, Silva,Marcos Tadeu Nolasco da, Vilela,Maria Marluce dos Santos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000400002
Resumo: CONTEXT AND OBJECTIVE: Adverse drug reactions are a significant problem in patients on antiretroviral therapy (ART). We determined liver enzyme elevation frequencies in HIV-infected children and adolescents receiving ART, and their association with risk factors. DESIGN AND SETTING: Cross-sectional study, at the Pediatrics Immunodeficiency Division, University Hospital, Universidade Estadual de Campinas. METHODS: Medical records of 152 children and adolescents (54.6% male; median age 7.48 years) were analyzed, with a mean of 2.6 liver enzyme determinations per patient. Clinically, patients were classified in categories N (6), A (29), B (78) and C (39). Serum levels of aspartate aminotransferase and alanine aminotransferase were evaluated. Hepatotoxicity was scored as grade 1 (1.1-4.9 times upper limit of normality, ULN), grade 2 (5.0-9.9 times ULN), grade 3 (10.0-15.0 times ULN) and grade 4 (> 15.0 times ULN). To assess hepatotoxicity risk factors, odds ratios (OR) and adjusted odds ratios (aOR) for age, gender, TCD4+ cell count, viral load and medication usage were calculated. RESULTS: We observed grade 1 hepatotoxicity in 19.7 % (30/152) patients. No cases of grade 2, 3 or 4 were detected. There was a significant association between hepatotoxicity and use of sulfonamides (OR, 3.61; 95% confidence interval (CI), 1.50-8.70; aOR, 3.58; 95% CI, 1.44-8.85) and antituberculous agents (OR, 9.23; 95% CI, 1.60-53.08; aOR, 9.05; 95% CI, 1.48-55.25). No toxicity was associated with ART. CONCLUSIONS: One fifth of patients experienced mild hepatotoxicity, attributed to antituberculous agents and sulfonamides. Our results suggest that ART was well tolerated.
id APM-1_36b2ef43c5062643d1cc5d12f7da5469
oai_identifier_str oai:scielo:S1516-31802007000400002
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapyAidsPediatricsHighly active antiretroviral therapyDrug toxicityAnti-bacterial agentsCONTEXT AND OBJECTIVE: Adverse drug reactions are a significant problem in patients on antiretroviral therapy (ART). We determined liver enzyme elevation frequencies in HIV-infected children and adolescents receiving ART, and their association with risk factors. DESIGN AND SETTING: Cross-sectional study, at the Pediatrics Immunodeficiency Division, University Hospital, Universidade Estadual de Campinas. METHODS: Medical records of 152 children and adolescents (54.6% male; median age 7.48 years) were analyzed, with a mean of 2.6 liver enzyme determinations per patient. Clinically, patients were classified in categories N (6), A (29), B (78) and C (39). Serum levels of aspartate aminotransferase and alanine aminotransferase were evaluated. Hepatotoxicity was scored as grade 1 (1.1-4.9 times upper limit of normality, ULN), grade 2 (5.0-9.9 times ULN), grade 3 (10.0-15.0 times ULN) and grade 4 (> 15.0 times ULN). To assess hepatotoxicity risk factors, odds ratios (OR) and adjusted odds ratios (aOR) for age, gender, TCD4+ cell count, viral load and medication usage were calculated. RESULTS: We observed grade 1 hepatotoxicity in 19.7 % (30/152) patients. No cases of grade 2, 3 or 4 were detected. There was a significant association between hepatotoxicity and use of sulfonamides (OR, 3.61; 95% confidence interval (CI), 1.50-8.70; aOR, 3.58; 95% CI, 1.44-8.85) and antituberculous agents (OR, 9.23; 95% CI, 1.60-53.08; aOR, 9.05; 95% CI, 1.48-55.25). No toxicity was associated with ART. CONCLUSIONS: One fifth of patients experienced mild hepatotoxicity, attributed to antituberculous agents and sulfonamides. Our results suggest that ART was well tolerated.Associação Paulista de Medicina - APM2007-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000400002Sao Paulo Medical Journal v.125 n.4 2007reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/S1516-31802007000400002info:eu-repo/semantics/openAccessGil,Ana Cecília MontesLorenzetti,RaquelMendes,Gun BergstenMorcillo,André MorenoToro,Adyléia Aparecida Dalbo ContreraSilva,Marcos Tadeu Nolasco daVilela,Maria Marluce dos Santoseng2007-10-31T00:00:00Zoai:scielo:S1516-31802007000400002Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2007-10-31T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
title Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
spellingShingle Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
Gil,Ana Cecília Montes
Aids
Pediatrics
Highly active antiretroviral therapy
Drug toxicity
Anti-bacterial agents
title_short Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
title_full Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
title_fullStr Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
title_full_unstemmed Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
title_sort Hepatotoxicity in HIV-infected children and adolescents on antiretroviral therapy
author Gil,Ana Cecília Montes
author_facet Gil,Ana Cecília Montes
Lorenzetti,Raquel
Mendes,Gun Bergsten
Morcillo,André Moreno
Toro,Adyléia Aparecida Dalbo Contrera
Silva,Marcos Tadeu Nolasco da
Vilela,Maria Marluce dos Santos
author_role author
author2 Lorenzetti,Raquel
Mendes,Gun Bergsten
Morcillo,André Moreno
Toro,Adyléia Aparecida Dalbo Contrera
Silva,Marcos Tadeu Nolasco da
Vilela,Maria Marluce dos Santos
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gil,Ana Cecília Montes
Lorenzetti,Raquel
Mendes,Gun Bergsten
Morcillo,André Moreno
Toro,Adyléia Aparecida Dalbo Contrera
Silva,Marcos Tadeu Nolasco da
Vilela,Maria Marluce dos Santos
dc.subject.por.fl_str_mv Aids
Pediatrics
Highly active antiretroviral therapy
Drug toxicity
Anti-bacterial agents
topic Aids
Pediatrics
Highly active antiretroviral therapy
Drug toxicity
Anti-bacterial agents
description CONTEXT AND OBJECTIVE: Adverse drug reactions are a significant problem in patients on antiretroviral therapy (ART). We determined liver enzyme elevation frequencies in HIV-infected children and adolescents receiving ART, and their association with risk factors. DESIGN AND SETTING: Cross-sectional study, at the Pediatrics Immunodeficiency Division, University Hospital, Universidade Estadual de Campinas. METHODS: Medical records of 152 children and adolescents (54.6% male; median age 7.48 years) were analyzed, with a mean of 2.6 liver enzyme determinations per patient. Clinically, patients were classified in categories N (6), A (29), B (78) and C (39). Serum levels of aspartate aminotransferase and alanine aminotransferase were evaluated. Hepatotoxicity was scored as grade 1 (1.1-4.9 times upper limit of normality, ULN), grade 2 (5.0-9.9 times ULN), grade 3 (10.0-15.0 times ULN) and grade 4 (> 15.0 times ULN). To assess hepatotoxicity risk factors, odds ratios (OR) and adjusted odds ratios (aOR) for age, gender, TCD4+ cell count, viral load and medication usage were calculated. RESULTS: We observed grade 1 hepatotoxicity in 19.7 % (30/152) patients. No cases of grade 2, 3 or 4 were detected. There was a significant association between hepatotoxicity and use of sulfonamides (OR, 3.61; 95% confidence interval (CI), 1.50-8.70; aOR, 3.58; 95% CI, 1.44-8.85) and antituberculous agents (OR, 9.23; 95% CI, 1.60-53.08; aOR, 9.05; 95% CI, 1.48-55.25). No toxicity was associated with ART. CONCLUSIONS: One fifth of patients experienced mild hepatotoxicity, attributed to antituberculous agents and sulfonamides. Our results suggest that ART was well tolerated.
publishDate 2007
dc.date.none.fl_str_mv 2007-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000400002
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802007000400002
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-31802007000400002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.125 n.4 2007
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209261774176256